{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(11)"],"submitter":["Le Rhun E"],"pubmed_abstract":["<h4>Importance</h4>Proton pump inhibitors (PPI) are often prescribed to prevent steroid-induced gastritis and peptic ulcer disease in patients with glioblastoma. Yet, these drugs may enhance the activity of aldehyde dehydrogenase 1 A1 (ALDH1A1), which has been linked to protection from oxidative stress, radiotherapy, and chemotherapy.<h4>Objective</h4>To explore the associations of the use of potent ALDH1A1-activating PPIs (PA-PPIs) and other antacid drugs with outcomes in patients with newly diagnosed glioblastoma.<h4>Design, setting, and participants</h4>This meta-analysis was a secondary analysis of individual prospectively captured patient data using a dataset of 5 randomized clinical trials conducted between 2008 and 2020. Participants included patients with a new diagnosis of gliobla"],"journal":["JAMA network open"],"pagination":["e2545578"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12648345"],"repository":["biostudies-literature"],"pubmed_title":["Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma."],"pmcid":["PMC12648345"],"pubmed_authors":["Weller M","Cloughesy T","Erridge SC","Nabors B","Reardon DA","Preusser M","Le Rhun E","Minniti G","Wick W","Stupp R","Sampson J","Mason W","Reijneveld JC","Gorlia T","Sain D","Roth P"],"additional_accession":[]},"is_claimable":false,"name":"Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.","description":"<h4>Importance</h4>Proton pump inhibitors (PPI) are often prescribed to prevent steroid-induced gastritis and peptic ulcer disease in patients with glioblastoma. Yet, these drugs may enhance the activity of aldehyde dehydrogenase 1 A1 (ALDH1A1), which has been linked to protection from oxidative stress, radiotherapy, and chemotherapy.<h4>Objective</h4>To explore the associations of the use of potent ALDH1A1-activating PPIs (PA-PPIs) and other antacid drugs with outcomes in patients with newly diagnosed glioblastoma.<h4>Design, setting, and participants</h4>This meta-analysis was a secondary analysis of individual prospectively captured patient data using a dataset of 5 randomized clinical trials conducted between 2008 and 2020. Participants included patients with a new diagnosis of gliobla","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T19:55:47.653Z","creation":"2026-05-21T03:09:22.198Z"},"accession":"S-EPMC12648345","cross_references":{"pubmed":["41288972"],"doi":["10.1001/jamanetworkopen.2025.45578"]}}